CCL5 and Alzheimer disease: Treatment with the acetylcholinesterase inhibitor pyridostigmine decreased CCL5 and CCR5 expression in PBMCs of AD patients; this was reversed by overexpression of Aβ1–42, which also increased IFN-γ expression but decreased that of IL-4.